NASDAQ:UPXI - Nasdaq - US39959A2050 - Common Stock - Currency: USD
11.01
+2.01 (+22.33%)
The current stock price of UPXI is 11.01 USD. In the past month the price increased by 349.39%. In the past year, price increased by 10.65%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
UL | UNILEVER PLC-SPONSORED ADR | 24.14 | 157.76B | ||
KVUE | KENVUE INC | 20.12 | 44.01B | ||
EL | ESTEE LAUDER COMPANIES-CL A | 24.16 | 20.60B | ||
BRBR | BELLRING BRANDS INC | 35.54 | 9.48B | ||
COTY | COTY INC-CL A | 17.61 | 4.30B | ||
IPAR | INTERPARFUMS INC | 20.62 | 3.46B | ||
ELF | ELF BEAUTY INC | 18.1 | 3.21B | ||
ODD | ODDITY TECH LTD-CL A | 21.87 | 2.38B | ||
EPC | EDGEWELL PERSONAL CARE CO | 10.47 | 1.47B | ||
OLPX | OLAPLEX HOLDINGS INC | 11.55 | 844.07M | ||
HLF | HERBALIFE LTD | 3.34 | 662.76M | ||
HNST | HONEST CO INC/THE | N/A | 491.18M |
Upexi, Inc. engages in the development, manufacturing, and distribution of consumer products through direct-to-consumer network, wholesale partnerships, and major third-party platforms like Amazon. The company is headquartered in Tampa, Florida and currently employs 64 full-time employees. The company went IPO on 2021-06-24. The firm focuses on direct-to-consumer and Amazon brands. The Company’s brands include LuckyTail, PRAX, Cure Mushrooms, Moonwlkr, Gumi Labs, and Upexi Distribution. LuckyTail products consist of its flagship nail grinder and healthy all-natural pet supplements. Gumi Labs manufactures gummies and other products supporting its health and wellness products, including those products manufactured with hemp ingredients. Upexi Distribution manages the warehousing and logistic needs of the Company and provides storage, consolidation, assembly, Amazon preparation, distribution and fulfilment services to its brands and its manufacturing operation.
UPEXI INC
3030 Rocky Point Drive, Suite 420
Tampa FLORIDA US
Employees: 64
Company Website: https://upexi.com/
Investor Relations: https://upexi.com/investors
Phone: 17013535425
The current stock price of UPXI is 11.01 USD. The price increased by 22.33% in the last trading session.
The exchange symbol of UPEXI INC is UPXI and it is listed on the Nasdaq exchange.
UPXI stock is listed on the Nasdaq exchange.
6 analysts have analysed UPXI and the average price target is 25.5 USD. This implies a price increase of 131.61% is expected in the next year compared to the current price of 11.01. Check the UPEXI INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
UPEXI INC (UPXI) has a market capitalization of 14.53M USD. This makes UPXI a Nano Cap stock.
UPEXI INC (UPXI) currently has 64 employees.
The Revenue of UPEXI INC (UPXI) is expected to grow by 8.09% in the next year. Check the estimates tab for more information on the UPXI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
UPXI does not pay a dividend.
UPEXI INC (UPXI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-21.83).
The outstanding short interest for UPEXI INC (UPXI) is 2.02% of its float. Check the ownership tab for more information on the UPXI short interest.
ChartMill assigns a technical rating of 8 / 10 to UPXI. When comparing the yearly performance of all stocks, UPXI is one of the better performing stocks in the market, outperforming 98.34% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to UPXI. UPXI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months UPXI reported a non-GAAP Earnings per Share(EPS) of -21.83. The EPS decreased by -1756.9% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -130.02% | ||
ROE | -605.68% | ||
Debt/Equity | 0.35 |
ChartMill assigns a Buy % Consensus number of 43% to UPXI. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 30.61% and a revenue growth 8.09% for UPXI